BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25492515)

  • 1. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
    Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
    Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
    Saijo K; Katoh T; Shimodaira H; Oda A; Takahashi O; Ishioka C
    Cancer Sci; 2012 Nov; 103(11):1994-2001. PubMed ID: 22924958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.
    Saijo K; Imai H; Chikamatsu S; Narita K; Katoh T; Ishioka C
    Cancer Sci; 2017 Jul; 108(7):1469-1475. PubMed ID: 28406576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Synthetic Study on Bicyclic Depsipeptides Containing an Intramolecular Disulfide Bond].
    Narita K
    Yakugaku Zasshi; 2022; 142(9):917-926. PubMed ID: 36047217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E; Barlocco D
    Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11.
    Imai H; Saijo K; Chikamatsu S; Kawamura Y; Ishioka C
    Cancer Sci; 2021 Feb; 112(2):792-802. PubMed ID: 33274548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
    Li LH; Zhang PR; Cai PY; Li ZC
    Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
    Son DS; Wilson AJ; Parl AK; Khabele D
    Cancer Biol Ther; 2010 Jun; 9(11):928-35. PubMed ID: 20404564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide.
    Mizutani H; Hiraku Y; Tada-Oikawa S; Murata M; Ikemura K; Iwamoto T; Kagawa Y; Okuda M; Kawanishi S
    Cancer Sci; 2010 Oct; 101(10):2214-9. PubMed ID: 20624163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
    Bahr JC; Robey RW; Luchenko V; Basseville A; Chakraborty AR; Kozlowski H; Pauly GT; Patel P; Schneider JP; Gottesman MM; Bates SE
    Oncotarget; 2016 Oct; 7(43):69804-69815. PubMed ID: 27634878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
    Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors from microorganisms: the Astellas experience.
    Masuoka Y; Shindoh N; Inamura N
    Prog Drug Res; 2008; 66():335, 337-59. PubMed ID: 18416310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
    Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
    J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
    Kobayashi Y; Ohtsuki M; Murakami T; Kobayashi T; Sutheesophon K; Kitayama H; Kano Y; Kusano E; Nakagawa H; Furukawa Y
    Oncogene; 2006 Jan; 25(4):512-24. PubMed ID: 16186804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
    Yurek-George A; Cecil AR; Mo AH; Wen S; Rogers H; Habens F; Maeda S; Yoshida M; Packham G; Ganesan A
    J Med Chem; 2007 Nov; 50(23):5720-6. PubMed ID: 17958342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total synthesis of bicyclic depsipeptides spiruchostatins C and D and investigation of their histone deacetylase inhibitory and antiproliferative activities.
    Narita K; Fukui Y; Sano Y; Yamori T; Ito A; Yoshida M; Katoh T
    Eur J Med Chem; 2013 Feb; 60():295-304. PubMed ID: 23313638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells.
    Kodani M; Igishi T; Matsumoto S; Chikumi H; Shigeoka Y; Nakanishi H; Morita M; Yasuda K; Hitsuda Y; Shimizu E
    Oncol Rep; 2005 Mar; 13(3):477-83. PubMed ID: 15706421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.